Eli Lilly's Mounjaro launches in India, outpacing Novo Nordisk in weight-loss drug race

Eli Lilly has moved first. On the Indian market for weight-loss and diabetes drugs, the pharmaceutical giant has launched Mounjaro—a once-weekly injection that targets two separate hormonal pathways in the body—before its closest competitor, Novo Nordisk, can get its own drug to patients. The timing matters. India is in the grip of a dual health crisis: diabetes cases are expected to nearly double from 74.2 million in 2021 to 124 million by 2045, and obesity is climbing sharply among working-age adults. A government survey from 2019 to 2021 found that nearly a quarter of women and men between 15 and 49 are overweight or obese, up from about one-fifth just a few years earlier. Into this landscape comes Mounjaro, priced at ₹4,375 for a 5 mg vial—roughly ₹16,000 per month for a standard dose—with the promise of controlling blood sugar while also triggering significant weight loss.

The drug works by mimicking two hormones that the body naturally produces: glucagon-like peptide-1 and gastric inhibitory polypeptide. Together, these signals regulate blood sugar, suppress appetite, and slow the movement of food through the digestive system, leaving patients feeling full longer. This dual action is what sets Mounjaro apart from Ozempic, the weight-loss drug that has become a cultural phenomenon in wealthier countries. Ozempic targets only the GLP-1 pathway. In clinical trials, Mounjaro delivered weight loss of 20 to 25 percent of body weight over 72 weeks—roughly 20 kilograms for many patients—compared to up to 15 percent for Ozempic. For people with Type 2 diabetes who also struggle with their weight, the drug offers a single solution to both problems.

But the benefits come with real risks. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and acid reflux. In some cases, severe diarrhea can lead to dehydration and acute kidney injury. Rapid weight loss itself can trigger gallbladder problems—gallstones and inflammation—in some patients. The drug is not suitable for pregnant women, children, or anyone with Type 1 diabetes. It is strictly forbidden for people with a history of medullary thyroid cancer or Multiple Endocrine Neoplasia Type 2 syndrome, a rare genetic condition that increases cancer risk. Patients with severe gastrointestinal disorders or a history of pancreatitis should also avoid it.

Novo Nordisk's Wegovy—which contains semaglutide, the same active ingredient as Ozempic—has already been approved by India's drug regulator, but the company has not yet launched it in the country. Reports suggest the company is aiming for a 2025 debut, ahead of its global target of 2026. The race matters because the global weight-loss drug market is expected to reach $150 billion within the next decade. By 2026, semaglutide's patent will expire in India, opening the door for local manufacturers to produce cheaper generic versions. For now, though, Lilly has the advantage. Mounjaro's dual mechanism gives it a clinical edge in weight management that Wegovy cannot match.

The entry of these drugs into India represents a significant shift in how the country might address its obesity and diabetes epidemics. For decades, treatment options have been limited to lifestyle changes, older medications, and insulin. Now, for patients who can afford them, there is a new tool—one that works on the body's own hunger and blood-sugar systems rather than forcing change through willpower alone. Whether these drugs will be accessible to the millions who need them most remains an open question. At ₹16,000 per month, Mounjaro is expensive by Indian standards, though far cheaper than the $1,086 monthly list price in the United States. As the market develops and generic alternatives emerge, the calculus may shift. For now, Eli Lilly has made the first move, and the Indian health system is watching to see what comes next.